WP4 will establish a data-sharing platform that will effectively exploit the data that has been pulled from multiple sources. This platform will provide descriptive and predictive information on seven types of HMs, thus improving decision-making and the treatment of patients. The creation of statistical models will identify the best practices that will enable the best evidence to be generated. WP4 will use the most innovative methods of data analysis and the most advanced algorithms in order to achieve the optimum management and mining of the data that has been collected.
Bayer, Celgene, EBMT, ELN, EORTC, GMV, HULAFE, IBSAL, Janssen, LeukaNET, MediUni Wien, Menarini, Novartis, Takeda, Ulm University, UNIBO, University of York.
Public-private partnership for Big Data in Hematology
HARMONY and HARMONY PLUS are funded through the Innovative Medicines Initiative (IMI), Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients. Funding is received from the IMI 2 Joint Undertaking and is listed under grant agreement for HARMONY No. 116026 and grant agreement for HARMONY PLUS No. 945406. This Joint Undertaking receives support from the European Union’s Horizon 2020 Research and Innovation Programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA).
HARMONY Coordination Office
Institute of Biomedical Research of
Salamanca (IBSAL)
Salamanca, Spain
HARMONY Communications
European Hematology Association (EHA)
The Hague, The Netherlands
